SCHEMBL1008457

SCHEMBL1008457

CN[C@H]1CCN(CC(N)=O)C1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.46
PKM P14618 2/20 0.46
TSHR P16473 1/20 0.46
KDM4E B2RXH2 3/20 0.40
PRKCI P41743 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
HRH4 Q9H3N8 2/20 0.35
LTA4H P09960 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HRH2 P25021 1/20 0.34
HRH1 P35367 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
HTT P42858 1/20 0.33
CARM1 Q86X55 1/20 0.33
PRMT6 Q96LA8 1/20 0.33
SFRP1 Q8N474 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15707100 1.00 POLB (0.46) POLBPKMTSHRKDM4EPRKCI
SCHEMBL1007721 1.00 POLB (0.46) POLBPKMTSHRKDM4EPRKCI
SCHEMBL10316243 0.89 PKM (0.49) POLBPKMTSHRKDM4ESMN1; SMN2
SCHEMBL19080601 0.85 POLB (0.44) POLBPKMTSHRKDM4EPRKCI
SCHEMBL27353549 0.84 LTA4H (0.35) POLBPKMHRH4LTA4HALDH1A1
SCHEMBL13693715 0.83 L3MBTL1 (0.46) POLBPKMTSHRKDM4ESMN1; SMN2
SCHEMBL6258214 0.83 POLB (0.48) POLBPKMTSHRKDM4EPRKCI
SCHEMBL21550370 0.82 HRH3 (0.34) POLBPKMTSHRSMN1; SMN2HRH4
SCHEMBL26812175 0.82 L3MBTL1 (0.38) POLBKDM4EALDH1A1HTTL3MBTL1
SCHEMBL16103858 0.82 L3MBTL1 (0.38) POLBKDM4EALDH1A1HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105488-A1 SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN CHLORION PHARMA, INC. (CA) 2011-05-05 US claimed
EP-2268616-A1 SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN Chlorion Pharma, Inc. (CA) 2011-01-05 EP claimed
WO-2009114950-A1 SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN CHLORION PHARMA, INC. (CA) 2009-09-24 WO claimed
US-20110105488-A1 SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN CHLORION PHARMA, INC. (CA) 2011-05-05 US disclosed
WO-2009114950-A1 SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN CHLORION PHARMA, INC. (CA) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105488-A1 SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN PAM, PNN, NOD1 POLB 1933/4885PKM 582/4885TSHR 4503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.